Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided-Reference-Cited by-同舟云学术

Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided

Published:2018-10-11 Issue:12 Volume:84 Page:2903-2913
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Huppertz Andrea¹^ORCID,Werntz Lars¹^ORCID,Meid Andreas D.¹^ORCID,Foerster Kathrin I.¹,Burhenne Jürgen¹^ORCID,Czock David¹^ORCID,Mikus Gerd¹^ORCID,Haefeli Walter E.¹^ORCID

Affiliation:

1. Department of Clinical Pharmacology and Pharmacoepidemiology; Heidelberg University Hospital; Im Neuenheimer Feld 410 69120 Heidelberg Germany

Funder

Actelion Pharmaceuticals

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13757/fullpdf

Reference54 articles.

1. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT);Galiè;Eur Heart J,2016

2. Pulmonary hypertension;Hoeper;Dtsch Arztebl Int,2017

3. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA);Olsson;Circulation,2014

4. Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL);Preston;Circulation,2015

5. Net clinical benefit of non-vitamin K antagonist oral anticoagulants versus warfarin in phase III atrial fibrillation trials;Renda;Am J Med,2015

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH;Blood Reviews;2024-09

2. Dose‐dependent induction of CYP3A activity by St. John's wort alone and in combination with rifampin;Clinical and Translational Science;2024-08

3. Differential inhibition of sildenafil and macitentan on saxagliptin metabolism;Toxicology and Applied Pharmacology;2024-05

4. Extracellular Vesicles as Surrogates for the Regulation of the Drug Transporters ABCC2 (MRP2) and ABCG2 (BCRP);International Journal of Molecular Sciences;2024-04-08

5. Effects of bergapten on the pharmacokinetics of macitentan in rats both in vitro and in vivo;Frontiers in Pharmacology;2023-07-10